Quantitative survey of certain substances of abuse in the adolescent and young adult population of SC. Survey study will be focused on substances of abuse that are easily accessible at a gas station due to little to no regulations or excessive amounts available in various forms such as Kratom, 7-OH, Tia, nicotine pouches, THC, etc.

This study is designed to improve how body image distress is identified among adult survivors of head and neck cancer during routine clinic visits. Participants will complete questionnaires about body image concerns either on paper or electronically (in clinic or remotely through a secure link). The study will evaluate how well a brief screening questionnaire (IMAGE-HN SF) identifies patients experiencing meaningful body image distress compared with the longer, full IMAGE-HN survey. In addition to assessing how accurately the short form performs, we will ask patients how they prefer the screening to be delivered, including the timing, format, and method of completion in routine care. A subset of participants will be invited to complete a short interview to share additional thoughts about how this type of screening should be implemented. Findings from this study will help guide the use of efficient and patient-centered body image screening in head and neck cancer clinics.

This an observational study collecting data for up to 8 years on patients who have been diagnosed with PiZZ or PiSZ Alpha-1 Antitrypsin Deficiency with or without liver disease. Patients' clinical, medical, and laboratory data will be collected prospectively per routine care and questionnaires will be collected during the clinic visits with the hopes of getting a better understanding of the natural progress of lung and liver disease associated with Alpha-1 Antitrypsin Deficiency.

This is a descriptive study designed to determine the proportion of women who are sexually active after minimally invasive sacrocolpopexy, with particular focus on those aged 65 and older. Because sacrocolpopexy carries certain risks—especially in older women—but also preserves vaginal length and may improve sexual function, understanding post-surgical sexual activity can help clinicians counsel patients when choosing between reconstructive surgeries, which preserve vaginal length, and obliterative surgeries, which do not. The study also aims to better understand patient values in surgical decision-making related to sexual activity. Women who had sacrocolpopexy at MUSC since January 1, 2015 will be contacted to complete two questionnaires: one assessing sexual activity and satisfaction with surgery, and one assessing sexual function using an adapted PISQ-IR questionnaire. Data will be analyzed using descriptive and comparative statistics to examine the proportion of sexually active women in groups under 65 versus 65 and older, as well as to compare their sexual function outcomes.

This study aims to improve cancer survivorship care work by refining how primary care providers and cancer specialists share responsibilities. Researchers want to understand how technology can help these teams communicate more clearly and effectively to coordinate care for survivors. The study team will use surveys, conduct interviews and organize focus groups for interested and eligible participants as methods of data collection to inform the research. Oncologists, Primary Care Physicians, administrative leads and colon or rectal cancer survivors that meet the eligibility criteria will complete surveys, engage in interviews and group discussions from each perspective to learn strategies to improve care, including who should handle which parts of survivorship care. Using this information, the team will create an intervention plan called PRIMES that outlines strategies to overcome common barriers. The ultimate goal is to help survivors receive better and more coordinated follow‑up care.

This study will evaluate whether using cold therapy before Anterior Cruciate Ligament (ACL) reconstruction surgery improves recovery during the first six weeks after surgery. Patients undergoing ACL reconstruction will either receive standard preoperative care or standard care plus a period of cold therapy prior to surgery. Pain levels, swelling, medication use, and functional recovery will be tracked using surveys and routine clinical follow-up information. participation will not change the surgical procedure or postoperative rehabilitation plan.

This study is for adult patients with Oral Squamous Cell Carcinoma (OSCC). The purpose of this study is to use results from a CLIA regulated blood test (NavDx) to measure tumor DNA to omit postoperative radiotherapy following surgery. Participation will include standard of care visits along with questionnaires and blood draws completed for research purposes. Participation in this study is anticipated to last approximately 2 years with a 3 year follow up period.

This study is for patients that have been diagnosed with locally advanced or metastatic solid tumor, including non-small cell lung cancer (NSCLC), triple-negative breast cancer, gastric cancer, esophageal cancer (or gastroesophageal cancer), head and neck squamous cell cancer, ovarian cancer, endometrial cancer, or cervical cancer. The study is testing and investigational drug called NRM-823. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). The primary purpose of this study is to evaluate the safety and tolerability of NRM-823 as monotherapy and in combination with pembrolizumab. The study drug is given as an injection into the stomach (or another place, like the thigh). An injection is like a shot between the skin and muscle so that the drug can enter your body. Participants can expect to be on this study until the first radiographic disease progression.

This study is for patients that have been newly diagnosed with GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL). This study is testing an investigational drug called zilovertamab vedotin. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). In the study, participants will be randomized to two different groups (like flipping a coin). The first group will receive zilovertamab vedotin plus R-CHP [rituximab, cyclophosphamide, doxorubicin, and prednisone]. The second group will receive the standard care regimen: polatuzumab vedotin plus R-CHP. The drugs will be given through an IV, and prednisone may be given to participants by mouth. The primary purpose of the study is to learn if zilovertamab vedotin plus R-CHP is safe and effective for treating DLBCL. Participants in this study can expect to be in this study for up to 5.5 years. The first six months will be participation in treatment, and the following five years will be follow-up.

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel group, efficacy, and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with a DSM-IV-TR diagnosis of ADHD. Approximately 286 subjects will be randomized to either SPN-812 or matching placebo in a 1:1 ratio (143 subjects per arm). Following up to 4 weeks of screening, subjects will be treated with study medication (SM) for 6 weeks, then will either be enrolled in a separate OLE study or followed for an additional 1 week for safety. The total duration of the study is up to 10 weeks.